The Legal Status of Fat-Loss Peptides

What "research use only" means legally

Most fat-loss peptides sold online arrive with a label that says "for research use only" or "not for human consumption." Sellers use that wording to argue they're supplying lab chemicals rather than drugs, since a drug sold for human use needs FDA approval first.

As of October 2026, US regulators don't accept that argument when the rest of the website points to human use. In warning letters dated August 24, 2026, FDA told several online peptide sellers that their products were unapproved new drugs despite the research-only labels. The letters quoted product pages describing weight loss. They also treated bacteriostatic water sold alongside the vials as evidence that the peptides were meant to be injected by people, as were the peptide guides and dosing calculators some sites offered. In two of the letters, FDA classed the bacteriostatic water itself as an unapproved drug.

The products named across those letters included retatrutide and tesamorelin, plus vials labeled as semaglutide and tirzepatide. FDA's page on unapproved GLP-1 drugs says the same thing in general terms: products "falsely labeled" for research purposes are illegal when they're sold for people to use.

Who carries the legal risk

US drug law mostly targets selling, not owning. The violations FDA cites in these letters concern introducing unapproved drugs into interstate commerce, which is what sellers do.

Criminal cases have followed the same pattern. On July 30, 2026, a federal judge in Indiana sentenced Matthew Kawa, owner of the online store Paradigm Peptides, to 70 months in prison. He had pleaded guilty to introducing unapproved drugs into interstate commerce and to illegal importing. According to the Justice Department, the store falsely claimed FDA registration and US manufacturing, and many products sold as SARMs actually contained testosterone. CBS News called the sentence a rare criminal penalty for a seller of "research use" peptides.

We found no US case against a buyer for simply possessing a peptide that isn't a controlled substance. That doesn't make buying risk-free. Rules abroad can be stricter (Australia has fined individuals for importing unapproved peptides, covered below), and buyers carry all of the product risk. Health Canada's April 2026 advisory warns that unauthorized peptide vials can hold the wrong amount of the active ingredient or unlisted ingredients. Some carry contaminants, anything from heavy metals to bacteria and endotoxins.

Prescription GLP-1 drugs are a separate legal category

Semaglutide and tirzepatide are approved prescription medicines in the US. Semaglutide is sold as Wegovy for weight management and Ozempic for type 2 diabetes, and FDA approved Wegovy tablets for weight management in December 2025. Tirzepatide is sold as Zepbound for weight management and Mounjaro for diabetes. Getting either one through a prescriber and a licensed pharmacy is fully legal; how fat-loss peptides compare on evidence covers what the trials showed.

The same molecule sold as a research vial is a different legal product. FDA says these vials may be counterfeit or hold the wrong amount of drug, or the wrong ingredient altogether. It also says semaglutide salt forms, such as semaglutide sodium, are different active ingredients from the one in the approved drug, and that it knows of no lawful basis for compounding with them.

Retatrutide, an investigational drug, isn't approved anywhere as of October 2026. FDA lists it among the GLP-1-type drugs it has warned companies for selling as research products.

Tesamorelin is an approved prescription drug too, sold as Egrifta, but only to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. A doctor prescribing it for general fat loss would be using it off-label. Research vials of tesamorelin were among the products in FDA's August 2026 letters.

Compounding rules for GLP-1 drugs

During the shortages that began in 2022, compounding pharmacies could legally make copies of semaglutide and tirzepatide, because federal law allows copies of drugs on FDA's shortage list. FDA declared the tirzepatide shortage over in December 2024 and the semaglutide shortage over on February 21, 2025. After grace periods that ended in spring 2025, compounders lost that basis for making copies of the approved products.

On April 30, 2026, FDA proposed keeping semaglutide and tirzepatide (along with liraglutide) off the 503B bulks list, which governs what outsourcing facilities may compound from bulk ingredients. The agency said it found no clinical need. As of October 2026, the comment period has closed and FDA hasn't published a final decision.

Compounding rules for GH secretagogues and other peptides

The 503A bulks list sets which bulk ingredients state-licensed pharmacies may compound with. As of October 2026, it names no peptides. Before late 2023, many compounders made peptides like ipamorelin under an FDA interim policy that tolerated compounding with nominated substances while FDA reviewed them. Toleration was never the same as being on the list.

Ipamorelin's status is often misdescribed. FDA put ipamorelin acetate in Category 2 (substances that may pose significant safety risks) on September 29, 2023, but under its 503B policy for outsourcing facilities. Its 503A nomination was withdrawn in September 2024. At an October 2024 meeting, FDA's Pharmacy Compounding Advisory Committee (PCAC) still voted 0-12 against adding it to the 503A list. As of October 2026, ipamorelin sits in FDA's "nominated but withdrawn" table, in no 503A category, so there's no lawful route to compound it under 503A either. FDA cites deaths reported in an intravenous study for gastric motility, and says it lacks safety data for other injection routes. Our page on what ipamorelin does and doesn't do for fat loss covers the trial evidence.

CJC-1295 and AOD-9604 sit in the same withdrawn table. For CJC-1295, FDA lists an increased heart rate and a body-wide vasodilatory reaction among serious adverse events. For AOD-9604, it notes serious adverse events whose cause isn't clear.

In April 2026, FDA removed 12 peptides from 503A Category 2 after their nominations were withdrawn; MOTS-c was one of them. The law firm Orrick noted at the time that removal doesn't place a peptide on the bulks list or in Category 1, which leaves it in a regulatory gray area. In July 2026 the PCAC voted to recommend six of the seven peptides it reviewed for the 503A list, including MOTS-c, against the advice of FDA staff. The votes are advisory. As of October 2026, FDA hasn't proposed a rule, so none of the six can lawfully be compounded yet.

HGH Fragment 176-191 has no approval anywhere and no compounding route we could find. Its closer-studied relative is covered in our page on HGH Fragment 176-191 and AOD-9604.

Where common fat-loss peptides stand (October 2026)

Outside the US

Several other regulators made the same point about research labels in 2026.

• Canada: Health Canada's April 9, 2026 advisory says "For Research Use Only" labelling "does not make these products legal." Its list of seized peptides includes ipamorelin, CJC-1295, MOTS-c and retatrutide, and it notes that peptides are generally regulated as prescription drugs in Canada.
• Australia: A TGA safety advisory in April 2026 named retatrutide and CJC-1295 among unapproved peptide products and said research-use disclaimers don't change their status, according to Pharmacy Daily. A Mills Oakley review of enforcement notes that the TGA fined a Victorian individual for importing an unapproved peptide in 2024.
• UK: In May 2026 the MHRA made its largest-ever seizure of unlicensed weight-loss medicines, about 12,000 doses including retatrutide and tirzepatide, and arrested two people under the Human Medicines Regulations 2012.

Tested athletes

For athletes, FDA status doesn't matter much. WADA's 2026 Prohibited List names ipamorelin and CJC-1295 under S2.2.4 (growth hormone releasing factors) alongside tesamorelin. AOD-9604 and hGH 176-191 are named under S2.2.3 as growth hormone fragments. MOTS-c is named under S4.4.1 as an AMPK activator. All of these are banned at all times.

Semaglutide and tirzepatide aren't prohibited. They're in WADA's Monitoring Program, which tracks use without sanctioning it, and USADA says they stay there in 2027. According to USADA, the 2027 list (in force from January 1, 2027) also adds "peptides" to the S0 definition of non-approved substances. Our article on peptides and anti-doping rules covers sport in more detail.

What to watch next

• Whether FDA proposes a rule for the six peptides the PCAC recommended in July 2026. A second PCAC meeting on more withdrawn peptides is planned before the end of February 2027.
• FDA's final decision on keeping semaglutide and tirzepatide off the 503B bulks list.
• More FDA warning letters to research-use sellers, and whether enforcement ever reaches buyers.